Phase I/II study of everolimus combined with mFOLFOX-6 and bevacizumab for first –line treatment of metastatic colorectal cancer

Conclusions Everolimus plus mFOLFOX-6  + bevacizumab is tolerable and demonstrated preliminary efficacy for first-line mCRC. Further studies are warranted in PTEN deficiency.

Source: Investigational New Drugs - October 10, 2018 Category: Drugs & Pharmacology Source Type: research